CD8A and neoplasm: Others demonstrated that abemaciclib (CDK4/CDK6 inhibitor) significantly enhanced anti-tumor responses in cell lines, animal models and breast cancer patients by increasing the capacity of tumor cells to present antigen and reducing Treg levels resulting in decreased Treg/CD8 T-cell ratio [31, 32].